Nature Communications (May 2019)
miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8+ T cell fate
- Yun Ji,
- Jessica Fioravanti,
- Wei Zhu,
- Hongjun Wang,
- Tuoqi Wu,
- Jinhui Hu,
- Neal E. Lacey,
- Sanjivan Gautam,
- John B. Le Gall,
- Xia Yang,
- James D. Hocker,
- Thelma M. Escobar,
- Shan He,
- Stefania Dell’Orso,
- Nga V. Hawk,
- Veena Kapoor,
- William G. Telford,
- Luciano Di Croce,
- Stefan A. Muljo,
- Yi Zhang,
- Vittorio Sartorelli,
- Luca Gattinoni
Affiliations
- Yun Ji
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Jessica Fioravanti
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Wei Zhu
- Department of Bioinformatics, Inova Translational Medicine Institute
- Hongjun Wang
- Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health
- Tuoqi Wu
- National Human Genome Research Institute, National Institutes of Health
- Jinhui Hu
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Neal E. Lacey
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Sanjivan Gautam
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- John B. Le Gall
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Xia Yang
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- James D. Hocker
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Thelma M. Escobar
- Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Shan He
- Fels Institute for Cancer Research and Molecular Biology, Temple University
- Stefania Dell’Orso
- Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health
- Nga V. Hawk
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Veena Kapoor
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- William G. Telford
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Luciano Di Croce
- Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology
- Stefan A. Muljo
- Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Yi Zhang
- Fels Institute for Cancer Research and Molecular Biology, Temple University
- Vittorio Sartorelli
- Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health
- Luca Gattinoni
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- DOI
- https://doi.org/10.1038/s41467-019-09882-8
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 12
Abstract
The inability of T cells to properly mount anti-tumour immunity underlies failed cancer immune surveillance or therapy. Here the authors show that a microRNA, miR-155, suppresses Ship1 phosphatase expression to modulate epigenetic reprogramming of CD8 T cell differentiation via the Phf19/PRC2 axis, thereby implicating a novel aspect of cancer immunity regulation.
